News & Events

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time.

Link to Presentation:
https://pipersandler.zoom.us/rec/play/GhVkvb15ubHLp86Mjmho2RwTNJR9pPCa5SvZkzWNhE0cvLprLJsAzsM7AI1_2ks-ZlTSJ00gM1B4Kqi6.j2Ta0sR16WvOAYH8

###

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

Media Contacts:

Arleen Goldenberg
agoldenberg@vergescientific.com

202.930.4762

More News

Disc Medicine Announces $90 Millio...

Proceeds will be used to advance multiple programs in Disc’s hematology pipeline into phase 2 development Financing led by OrbiMed and includes...

Disc Medicine Appoints Will Savage...

Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs CAMBRIDGE,...

Disc Medicine Initiates Phase 1 Cl...

DISC-0974 is an investigational monoclonal antibody that utilizes a novel mechanism of action to suppress hepcidin, the master regulator of iron metabolism...

Disc Medicine Expands Hematology P...

Clinical-Stage Program is Positioned to Enter Phase 2 Study in Erythropoietic Protoporphyria (EPP) CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced...

Disc Medicine to Present at the Eu...

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine to Present at the Je...

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious...

Disc Medicine Appoints William Whi...

CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine to Present at the Vi...

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...

Disc Medicine Expands Scientific A...

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...

Disc Medicine to Present at Citi&#...

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...

Disc Medicine Expands Leadership T...

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development Cambridge, Mass. –...

John Quisel, JD, PhD Joins Disc Me...

Co-founder and Interim CEO Brian MacDonald to Serve as Senior Advisor and Director Cambridge, Mass. – January 28, 2020 – Disc Medicine,...

Disc Medicine Completes $50 Millio...

Cambridge, Mass. – October 29, 2019 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...

Disc Medicine Expands Pipeline Foc...

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...

Introducing Disc Medicine, a New H...

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...